Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 193

The DOI matches its Crossref record.

Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results

Open access
Atar, D., Arheden, H., Berdeaux, A., Bonnet, J.-L., Carlsson, M., Clemmensen, P., Cuvier, V., Danchin, N., Dubois-Rande, J.-L., Engblom, H., Erlinge, D., Firat, H., Halvorsen, S., Hansen, H. S., Hauke, W., Heiberg, E., Koul, S., Larsen, A.-I., Le Corvoisier, P., Nordrehaug, J. E., Paganelli, F., Pruss, R. M., Rousseau, H., Schaller, S., Sonou, G., Tuseth, V., Veys, J., Vicaut, E., Jensen, S. E. · 2015 · European Heart Journal

Abstract

AIM: The MITOCARE study evaluated the efficacy and safety of TRO40303 for the reduction of reperfusion injury in patients undergoing revascularization for ST-elevation myocardial infarction (STEMI). METHODS: Patients presenting with STEMI within 6 h of the onset of pain randomly received TRO40303 (n = 83) or placebo (n = 80) via i.v. bolus injection prior to balloon inflation during primary percutaneous coronary intervention in a double-blind manner. The primary endpoint was infarct size expressed as area under the curve (AUC) for creatine kinase (CK) and for troponin I (TnI) over 3 days. Secondary endpoints included measures of infarct size using cardiac magnetic resonance (CMR) and safety outcomes. RESULTS: The median pain-to-balloon time was 180 min for both groups, and the median (mean) door-to-balloon time was 60 (38) min for all sites. Infarct size, as measured by CK and TnI AUCs at 3 days, was not significantly different between treatment groups. There were no significant differences in the CMR-assessed myocardial salvage index (1-infarct size/myocardium at risk) (mean 52 vs. 58% with placebo, P = 0.1000), mean CMR-assessed infarct size (21.9 g vs. 20.0 g, or 17 vs. 15% of LV-mass) or left ventricular ejection fraction (LVEF) (46 vs. 48%), or in the mean 30-day echocardiographic LVEF (51.5 vs. 52.2%) between TRO40303 and placebo. A greater number of adjudicated safety events occurred in the TRO40303 group for unexplained reasons. CONCLUSION: This study in STEMI patients treated with contemporary mechanical revascularization principles did not show any effect of TRO40303 in limiting reperfusion injury of the ischaemic myocardium.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehu331

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 193

Metadata

Authors
Atar, D., Arheden, H., Berdeaux, A., Bonnet, J.-L., Carlsson, M., Clemmensen, P., Cuvier, V., Danchin, N., Dubois-Rande, J.-L., Engblom, H., Erlinge, D., Firat, H., Halvorsen, S., Hansen, H. S., Hauke, W., Heiberg, E., Koul, S., Larsen, A.-I., Le Corvoisier, P., Nordrehaug, J. E., Paganelli, F., Pruss, R. M., Rousseau, H., Schaller, S., Sonou, G., Tuseth, V., Veys, J., Vicaut, E., & Jensen, S. E.
Venue
European Heart Journal
Published
2014-09-01
Volume
36
Issue
2
Pages
112-119
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2143830716
Cited by
193
References
0
FWCI
20.50
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. https://app.cochat.ai/papers/10.1093/eurheartj/ehu331
The paper
Atar, D., Arheden, H., Berdeaux, A., Bonnet, J.-L., Carlsson, M., Clemmensen, P., Cuvier, V., Danchin, N., Dubois-Rande, J.-L., Engblom, H., Erlinge, D., Firat, H., Halvorsen, S., Hansen, H. S., Hauke, W., Heiberg, E., Koul, S., Larsen, A.-I., Le Corvoisier, P., . . . Jensen, S. E. (2015). Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. European Heart Journal. https://doi.org/10.1093/eurheartj/ehu331

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.